New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder with few curative options. After research conducted as part of the multicenter RUBY Trial, researchers have published their latest findings in the New England Journal of Medicine. Remarkably, 27 out of 28 patients did not have any painful sickle cell crises after treatment, achieving what physicians call a “functional cure.”
This article was originally published on MedicalXpress.com
